How Peptides Are Made: Solid-Phase Peptide Synthesis Explained

How Peptides Are Made: Solid-Phase Peptide Synthesis Explained

Every research peptide — whether BPC-157, TB-500, or a complex 44-amino acid GHRH analogue like Tesamorelin — is manufactured using a chemistry technique called solid-phase peptide synthesis (SPPS). Understanding this process is more than academic curiosity: it directly explains why peptide purity varies between suppliers, why certain compounds are more expensive to produce than others, and what quality control steps actually matter when evaluating a Certificate of Analysis.

This guide walks through SPPS from first principles — the core chemistry, the step-by-step synthesis cycle, common sources of impurity, and the purification process that determines final product quality.

All content is for educational and research purposes only.

Why Peptides Can't Just Be "Mixed Together"

Peptides are chains of amino acids linked by peptide bonds (amide bonds between the carboxyl group of one amino acid and the amino group of the next). A naive approach might assume you could simply combine 15 amino acids in a flask and let them react to form BPC-157. This does not work, for a fundamental chemical reason: amino acids have both an amino group and a carboxyl group, meaning uncontrolled mixing produces a random, uncontrolled polymerisation — a chaotic mixture of peptide fragments of random length and random sequence, not the single defined 15-residue chain required.

Solid-phase peptide synthesis solves this problem through a strategy of selective protection and stepwise, controlled addition — building the peptide chain one amino acid at a time, in a precisely controlled sequence, anchored to a solid support that allows excess reagents to be washed away between each step.

The Solid Support: Why "Solid-Phase"

SPPS anchors the growing peptide chain to an insoluble polymer resin bead (commonly polystyrene-based) via its C-terminal amino acid. This solid-phase anchoring is the innovation — developed by Bruce Merrifield in the 1960s, work for which he received the Nobel Prize in Chemistry — that makes modern peptide synthesis practical at scale.

Why solid-phase matters:

  • The growing peptide chain remains attached to the resin throughout synthesis
  • After each reaction step, the resin (with the attached peptide) can be simply filtered and washed — removing unreacted amino acids, coupling reagents, and by-products
  • This eliminates the need to purify the growing peptide chain after every single addition — a task that would be practically impossible for chains of 10+ amino acids using solution-phase methods
  • Only after the full sequence is assembled is the peptide cleaved from the resin

The Synthesis Cycle: Step by Step

SPPS proceeds through a repeating cycle for each amino acid added to the chain. Peptide synthesis conventionally proceeds from the C-terminus to the N-terminus — the opposite direction from how the sequence is written and read.

Step 1: Resin Loading

The first (C-terminal) amino acid, with its amino group temporarily protected, is attached to the solid resin via its carboxyl group.

Step 2: Deprotection

The protecting group on the amino group of the resin-bound amino acid is removed, exposing a free amino group ready to react with the next incoming amino acid. The two most common protection strategies are Fmoc (fluorenylmethyloxycarbonyl, removed under mild basic conditions) and Boc (tert-butyloxycarbonyl, removed under acidic conditions) — Fmoc chemistry is the more widely used modern approach due to its milder overall reaction conditions.

Step 3: Coupling

The next amino acid in the sequence — itself protected at its amino group, with its carboxyl group "activated" by a coupling reagent — is introduced. The activated carboxyl group reacts with the free amino group on the resin-bound chain, forming a new peptide bond and extending the chain by one residue.

Common coupling reagents include HBTU, HATU, and DIC/HOBt combinations — each activating the carboxyl group to make it reactive enough to form the peptide bond efficiently without also reacting with unwanted side chains.

Step 4: Washing

Excess unreacted amino acid and coupling reagent are washed away through the solid support, leaving only the resin-bound peptide chain (now one residue longer) for the next cycle.

Step 5: Repeat

Steps 2–4 repeat for every amino acid in the target sequence, building the chain one residue at a time until the complete sequence has been assembled.

Step 6: Side-Chain Deprotection and Cleavage

Once the full sequence is assembled, the peptide is cleaved from the solid resin, and any remaining protecting groups on amino acid side chains (many amino acids — including lysine, cysteine, serine, and others — require their reactive side chains to be protected throughout synthesis to prevent unwanted side reactions) are removed. This is typically accomplished with a strong acid treatment (commonly trifluoroacetic acid, TFA) — which is where TFA residue in the final product commonly originates.

Why Impurities Occur: Sources of Error in SPPS

Understanding where impurities come from explains why HPLC purity varies between synthesis runs and suppliers.

Incomplete Coupling (Deletion Sequences)

If a coupling reaction doesn't go to completion — some fraction of resin-bound chains fail to react with the incoming amino acid — the result is a mixture of full-length peptide and "deletion sequences" missing one or more residues. Longer peptides (like Tesamorelin's 44 residues) have more coupling steps and therefore more opportunities for incomplete coupling to accumulate deletion sequence impurities — one reason longer peptides are generally more expensive and challenging to produce at very high purity than shorter ones.

Incomplete Deprotection

If the protecting group removal (deprotection) step doesn't go to completion, some chains retain a blocked amino group and cannot react in the subsequent coupling step — again generating deletion or "capped" sequence impurities.

Racemisation

Under certain reaction conditions, particularly during coupling activation, amino acid stereocentres can undergo racemisation — converting some L-amino acid to the D-form. Since biological receptors are typically stereospecific, D-amino acid-containing impurities are generally biologically inactive contaminants that reduce effective purity even though they may be chemically similar to the target sequence.

Side-Chain Modification

Reactive amino acid side chains (particularly on cysteine, methionine, tryptophan, and serine) can undergo unwanted side reactions during synthesis or cleavage if protection strategies are imperfect — generating oxidised or otherwise modified variants of the target sequence.

Aggregation During Synthesis

Some peptide sequences are prone to forming secondary structure (beta-sheets) during synthesis, which can physically impede subsequent coupling reactions — a phenomenon called "difficult sequences" in the SPPS literature, requiring specialised reaction conditions to overcome.

Purification: HPLC and the Final Product

After cleavage from the resin, the crude peptide product is a mixture of the target full-length sequence plus the various impurities described above. Purification via preparative HPLC (high-performance liquid chromatography) separates the target peptide from these impurities based on differences in hydrophobicity, size, or charge.

The purification trade-off: Higher purity targets (99%+ vs. 95%) require more stringent HPLC purification, which reduces overall yield (some target peptide is inevitably lost in the process of removing closely-eluting impurities) and increases cost. This is why ≥99% purity peptides command a price premium over ≥95% — the additional purification effort and yield loss required to achieve that final few percentage points is substantial.

After purification, the peptide solution is typically lyophilized (freeze-dried) to produce the stable powder form in which research peptides are supplied — removing water to maximise shelf-stability, as covered in our peptide storage guide.

Why This Matters for Evaluating Research Peptides

Understanding SPPS chemistry directly informs how to evaluate a peptide supplier's quality claims:

Longer, more complex sequences are inherently harder to synthesise at high purity. A 44-amino acid Tesamorelin has vastly more opportunities for coupling/deprotection errors to accumulate than a 5-amino acid Ipamorelin. Expect (and verify via COA) that purity standards and pricing reflect this complexity.

TFA counter-ion presence is a normal consequence of the cleavage process, not necessarily a quality defect — but its concentration should be documented for cell-culture-sensitive applications, as covered in our How to Read a Third-Party Lab Test guide.

HPLC purity data is the direct downstream measure of how well the synthesis and purification process controlled for the impurities described above. A supplier's willingness to provide detailed, third-party verified HPLC and mass spectrometry data reflects confidence in a well-controlled synthesis and purification process.

Frequently Asked Questions

Is Fmoc or Boc chemistry "better" for research peptides? Fmoc chemistry is more widely used in modern commercial SPPS due to its milder reaction conditions (basic deprotection rather than repeated strong acid exposure), which reduces the risk of side reactions and degradation during synthesis — particularly relevant for longer or more complex sequences.

Why are some peptides so much more expensive than others? Sequence length, presence of "difficult" residues prone to side reactions or aggregation, and the target purity level are the primary cost drivers. A 44-amino acid sequence at 99% purity requires substantially more synthesis cycles and more stringent (yield-reducing) purification than a 5-amino acid sequence at 95% purity.

Does SPPS produce a peptide identical to the naturally occurring version? For peptides that replicate a native sequence (like Tesamorelin's native GHRH backbone), properly synthesised and purified SPPS product is chemically identical to the natural sequence at the target positions. Synthetic analogues with intentional modifications (like CJC-1295's DPP-IV resistance substitutions) are, by design, chemically distinct from any native sequence.

Can I tell from the COA whether the synthesis was well-controlled? Yes, indirectly — a high HPLC purity (≥99%) with a clean, single-peak chromatogram and matching mass spectrometry data indicates that the synthesis and purification process successfully minimised the deletion sequences, racemisation products, and side-chain modifications discussed above.

Conclusion

Solid-phase peptide synthesis is the chemistry foundation underlying every research peptide — a controlled, stepwise process of protection, coupling, deprotection, and purification that transforms individual amino acids into precisely sequenced chains. Understanding where impurities originate in this process — incomplete coupling, racemisation, side-chain modification — clarifies why purity verification through independent HPLC and mass spectrometry testing is not a bureaucratic formality but a direct check on synthesis quality.

Proto Peptide's research compounds are synthesised and independently third-party tested to verify purity and identity for every production lot. Browse our complete catalog and visit our Third Party Lab Tests page for current quality documentation.

Where to Buy Research-Grade Peptides in Canada and the USA

If you are sourcing high-purity research peptides, quality matters.

At Proto Peptide, we provide research-grade compounds including:

We ship across Canada and to the United States, offering reliable fulfillment and clearly labeled research products.

Shipping & support

We ship to Canadian research addresses and provide documentation (COA/COC) on request. If you need help with storage or dosing for in-lab protocols, check out our Reconstitution Guide and Peptide Storing Guide

Disclaimer

This content is intended for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new supplement or research compound. The statements provided have not been evaluated by the FDA or Health Canada and are subject to change as scientific understanding evolves. Always follow your institution’s guidelines and consult safety data sheets (SDS) before handling any research chemical.

Back to blog